Oxford BioMedica PLC (OXBDF)

[marcusl2]

Findings from the study suggest that CTL019, despite absent on most neoplastic plasma cell population, has the ability to favorably alter the clinical disease trajectory in multiple myeloma patients.

HTTP://insights.bio/cell-and-gene-therapy-insights/2018/04/25/car-t-therapy-in-combination-with-standard-therapy-improves-duration-of-response-in-multiple-myeloma-patients/